Join Growin Stock Community!

Tectonic therapeutic, inc.TECX.US Overview

US StockHealthcare
(No presentation for TECX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

TECX AI Insights

TECX Overall Performance

TECX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

TECX Recent Performance

2.58%

Tectonic therapeutic, inc.

-3.61%

Avg of Sector

-2.16%

S&P500

TECX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

TECX Key Information

TECX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

TECX Profile

Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.

Price of TECX

TECX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

TECX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.96
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
1.64
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.96
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
1.64
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is TECX's latest earnings report released?

    The most recent financial report for Tectonic therapeutic, inc. (TECX) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating TECX's short-term business performance and financial health. For the latest updates on TECX's earnings releases, visit this page regularly.

  • How much debt does TECX have?

    As of the end of the reporting period, Tectonic therapeutic, inc. (TECX) had total debt of 1.28M, with a debt ratio of 0. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does TECX have?

    At the end of the period, Tectonic therapeutic, inc. (TECX) held Total Cash and Cash Equivalents of 254.87M, accounting for 0.98 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is TECX's EPS continuing to grow?

    According to the past four quarterly reports, Tectonic therapeutic, inc. (TECX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.03. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of TECX?

    Tectonic therapeutic, inc. (TECX)'s Free Cash Flow (FCF) for the period is -14.46M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 14.05% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of TECX?

    The latest valuation data shows Tectonic therapeutic, inc. (TECX) has a Price-To-Earnings (PE) ratio of -6.06 and a Price/Earnings-To-Growth (PEG) ratio of -5.07. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.